ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $77.33 Consensus PT from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has received a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $77.33.

Several analysts have recently weighed in on ANIP shares. Piper Sandler started coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 target price for the company. Truist Financial lifted their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. HC Wainwright reiterated a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Finally, Raymond James raised their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Wednesday, September 18th.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 33,481 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the transaction, the chief executive officer now owns 370,378 shares in the company, valued at $21,478,220.22. The trade was a 8.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 33,981 shares of company stock worth $1,970,066 over the last quarter. Insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Pacer Advisors Inc. grew its stake in shares of ANI Pharmaceuticals by 23,259.8% during the third quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock worth $33,907,000 after acquiring an additional 565,910 shares during the last quarter. Bank of Montreal Can purchased a new stake in shares of ANI Pharmaceuticals during the third quarter worth about $13,043,000. Millennium Management LLC lifted its holdings in shares of ANI Pharmaceuticals by 1,005.8% during the second quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock worth $14,651,000 after purchasing an additional 209,272 shares during the period. Mizuho Markets Americas LLC acquired a new stake in shares of ANI Pharmaceuticals during the third quarter worth about $11,670,000. Finally, Barclays PLC lifted its holdings in shares of ANI Pharmaceuticals by 1,681.2% during the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock worth $8,534,000 after purchasing an additional 135,003 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Up 1.8 %

Shares of ANIP opened at $56.97 on Monday. The company has a market cap of $1.20 billion, a PE ratio of -103.58 and a beta of 0.73. The business has a fifty day moving average of $58.05 and a 200 day moving average of $60.43. ANI Pharmaceuticals has a 52-week low of $48.20 and a 52-week high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The business had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. During the same period last year, the company earned $1.05 earnings per share. The business’s revenue for the quarter was up 12.5% compared to the same quarter last year. On average, sell-side analysts expect that ANI Pharmaceuticals will post 3.87 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.